Chloroquine diphosphate (CQ), an autophagy inhibitor that may enhance the cytocidal effect of gefitinib against cSCC, was used in the present study. Suppression of autophagy by CQ, which was demonstrated by an alteration in microtubule associated protein 1 light chain 3-B in CQ pre-treated A431 cells, significantly enhanced cell apoptosis, which suggested that gefitinib-induced autophagy is cytoprotective. CQ was demonstrated to exhibit a synergistic apoptotic effect when used in combination with gefitinib during cSCC(cutaneous squamous cell carcinoma) therapy[2]. In vitro studies indicate that the antiviral effect of chloroquine diphosphate (CQ) requires a high concentration of the drug[3]. Chloroquine diphosphate (25mg/kg and 50mg/kg, respectively) significantly inhibited the growth of the implanted 4T1 tumor cells and induced apoptosis in the tumor microenvironment. Moreover, the metastasis of tumor cells to the lungs was inhibited significantly and the survival of the mice enhanced[4].
Chloroquine phosphate/磷酸氯喹 细胞实验
Cell Line
Concentration
Treated Time
Description
References
HK-2 cells
10 μM
24 h
CQ remarkably reversed the nilotinib-induced decrease in MMP and inhibited nilotinib-induced intracellular ROS accumulation.
Adv Sci (Weinh). 2023 Sep;10(26):e2302002.
HUVECs
10 μM
24 h
CQ remarkably reversed the nilotinib-induced decrease in MMP and inhibited nilotinib-induced intracellular ROS accumulation.
Adv Sci (Weinh). 2023 Sep;10(26):e2302002.
WS hMSCs
0.2-100 μM
Chloroquine at low concentrations (0.2-5 μM) promoted cell self-renewal, while higher concentrations (20 μM and above) inhibited cell proliferation. Treatment with 1 μM CQ decreased the percentage of SA-β-gal-positive cells and increased the number of Ki67-positive cells, while also reducing IL-6 secretion.
Protein Cell. 2022 Jun;13(6):454-461.
U2OS cells
10, 20, 40 μM
16 h
Induced eIF2α phosphorylation
Cell Death Dis. 2021 Jan 6;12(1):6.
U2OS-GFP-LC3 ATG5 knockout cells
10, 20, 40 μM
6 h
ATG5 knockout cells failed to accumulate autophagosomes
Chloroquine induced phosphorylation of KAP1 at S824 and ZEBRA expression, and the EBV lytic cycle reached completion, releasing substantial numbers of viral particles.
PLoS Pathog. 2017 Mar 1;13(3):e1006249.
Jijoye and Raji Burkitt lymphoma cells
200 μM
Chloroquine induced the expression of ZEBRA in both cell lines, although with different temporal patterns.
PLoS Pathog. 2017 Mar 1;13(3):e1006249.
Calu-3 cells
64.7 µM
Inhibit SARS-CoV-2 infection
J Mol Cell Biol. 2021 Jul 6;13(3):175-184.
Vero E6 cells
6.5 µM
Inhibit SARS-CoV-2 infection
J Mol Cell Biol. 2021 Jul 6;13(3):175-184.
HH514-16 Burkitt lymphoma cells
200 μM
24 h
Chloroquine induced phosphorylation of KAP1 at S824 and activated the EBV lytic cycle.
PLoS Pathog. 2017 Mar 1;13(3):e1006249.
MiaPaca-2
100 μM
72 h
To evaluate the cytotoxicity of CQ-HES, results showed that CQ-HES had similar cytotoxicity to HCQ.
Biomacromolecules. 2017 Aug 14;18(8):2247-2257.
MiaPaca-1
100 μM
72 h
To evaluate the cytotoxicity of CQ-HES, results showed that CQ-HES had similar cytotoxicity to HCQ.
Biomacromolecules. 2017 Aug 14;18(8):2247-2257.
AsPC-1
100 μM
72 h
To evaluate the cytotoxicity of CQ-HES, results showed that CQ-HES had similar cytotoxicity to HCQ.
Biomacromolecules. 2017 Aug 14;18(8):2247-2257.
Chloroquine phosphate/磷酸氯喹 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
C57BL/6J mice
Nilotinib-induced nephrotoxicity model
Oral
30 mg/kg
Daily for 30 days
HCQ significantly reversed the nilotinib-induced elevation of BUN and Scr and ameliorated kidney cell apoptosis and oxidative stress induced by nilotinib.
Adv Sci (Weinh). 2023 Sep;10(26):e2302002.
Sprague Dawley (SD) rats
Physiologically aged rat model
Oral
0.1 mg/kg
Twice a week for 5 months
Low-dose CQ treatment extended the lifespan of rats, repressed systemic inflammation, and inhibited fibrosis across multiple tissues. Furthermore, CQ treatment mitigated age-related molecular changes and repressed genes linked to fibrosis and the inflammatory response.
Colombia
... 展开 >> GSK Investigational Site
Recruiting
Monteria, Colombia
Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com
Contact: EU GSK Clinical Trials Call Center +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com
Thailand
GSK Investigational Site
Not yet recruiting
Tak, Thailand, 63110
Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com
Contact: EU GSK Clinical Trials Call Center +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com
Vietnam
GSK Investigational Site
Recruiting
Hanoi, Vietnam, 100000
Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com
Contact: EU GSK Clinical Trials Call Center +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com
GSK Investigational Site
Recruiting
Ho Chi Minh City, Vietnam, 700000
Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com
Contact: EU GSK Clinical Trials Call Center +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com
GSK Investigational Site
Recruiting
Ho Chi Minh, Vietnam
Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com
Contact: EU GSK Clinical Trials Call Center +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com 收起 <<
Cytotoxicity against human HeLa cells assessed as growth inhibition by MTT assay, IC50=30 μM
24354322
human HepG2 cells
Cytotoxic assay
48 h
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay, IC50=37.68 μM
23815186
human K562 cells
Cytotoxic assay
Cytotoxicity against human K562 cells by MTT assay, IC50=31.83 nM
18538567
human KB cells
Cytotoxic assay
Cytotoxicity against human KB cells by microplate method, IC50=0.6 μM
14640524
human MCF7 cells
Cytotoxic assay
48 h
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay in presence of 0.4 uM 1-(1-(4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one, GI50=5.51 μM
19945197
human MDA-MB-231 cells
Cytotoxic assay
48 h
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay in presence of 3.5 uM 4-(2-chloro-10H-phenoxazin-10-yl)-N,N-diethylbutan-1-amine hydrochloride, GI50=6.08 μM
19945197
human MDA-MB-468 cells
Cytotoxic assay
48 h
Cytotoxicity against human MDA-MB-468 cells after 48 hrs by SRB assay in presence of 3.5 uM 4-(2-chloro-10H-phenoxazin-10-yl)-N,N-diethylbutan-1-amine hydrochloride, GI50=2.81 μM
Colombia
... 展开 >> GSK Investigational Site
Recruiting
Monteria, Colombia
Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com
Contact: EU GSK Clinical Trials Call Center +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com
Thailand
GSK Investigational Site
Not yet recruiting
Tak, Thailand, 63110
Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com
Contact: EU GSK Clinical Trials Call Center +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com
Vietnam
GSK Investigational Site
Recruiting
Hanoi, Vietnam, 100000
Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com
Contact: EU GSK Clinical Trials Call Center +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com
GSK Investigational Site
Recruiting
Ho Chi Minh City, Vietnam, 700000
Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com
Contact: EU GSK Clinical Trials Call Center +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com
GSK Investigational Site
Recruiting
Ho Chi Minh, Vietnam
Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com
Contact: EU GSK Clinical Trials Call Center +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com 收起 <<
United States, Washington
... 展开 >>
Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases
Seattle, Washington, United States, 98101-1466 收起 <<
Terminated(Low prevalence of m... 展开 >>alaria, high prevalence of reported allergy to sulphur drugs, high proportion of women not meeting the inclusion criterea.) 收起 <<
August 2010
Solomon Islands
... 展开 >>
Honiara City Council
Honiara, Solomon Islands 收起 <<
China, Beijing
... 展开 >> Beijing Tiantan Hospital
Not yet recruiting
Beijing, Beijing, China
China, Shanghai
Huashan Hospital
Not yet recruiting
Shanghai, Shanghai, China, 200025
Ruijin Hosipital
Enrolling by invitation
Shanghai, Shanghai, China, 200025
China
Chinese PLA General Hospital
Not yet recruiting
Beijing, China
Peking Union Medical College Hospital
Recruiting
Beijing, China
Xinqiao Hospital of Chongqing
Not yet recruiting
Chongqing, China
First Affiliated Hospital of Fujian Medical
Recruiting
Fujian, China
First Hospital of China Medical University
Not yet recruiting
Shenyang, China
First Affiliated Hospital of Wenzhou Medical Univeristy
Recruiting
Wenzhou, China 收起 <<
Glioblastoma WHO Grade IV
... 展开 >> Diffuse Midline Glioma Histone 3 K27M WHO Grade IV
Anaplastic Astrocytoma WHO Grade III
Diffuse Intrinsic Pontine Glioma
Gliomatosis Cerebri 收起 <<
Phase 3
Recruiting
June 1, 2023
Germany
... 展开 >> Klinikum Augsburg
Recruiting
Augsburg, Germany
Contact: Michael Frühwald, Prof.
Evangelisches Krankenhaus Bielefeld
Recruiting
Bielefeld, Germany
Contact: Norbert Jorch, Dr.
Universitätsklinikum Bonn
Recruiting
Bonn, Germany
Contact: Carola Weber, Dr.
Klinikum Bremen-Mitte gGmbH
Recruiting
Bremen, Germany
Contact: Arnulf Pekrun, Prof.
Klinikum Chemnitz gGmbH
Recruiting
Chemnitz, Germany
Contact: André Hofmann, Dr.
Carl-Thiem-Klinikum Cottbus gGmbH
Recruiting
Cottbus, Germany
Contact: Georg Schwabe, PD Dr.
Sana Kliniken Duisburg GmbH - Wedau Kliniken
Recruiting
Duisburg, Germany
Contact: Tanja Höll, Dr.
Universitätsklinikum Erlangen
Recruiting
Erlangen, Germany
Contact: Markus Metzler, Prof.
Universitätsklinikum Freiburg
Recruiting
Freiburg, Germany
Contact: Charlotte Niemeyer, Prof.
Universitätsmedizin Greifswald
Recruiting
Greifswald, Germany
Contact: Holger Lode, Prof.
Universitätsmedizin Göttingen
Recruiting
Göttingen, Germany
Contact: Christof Kramm, Prof.
Universitätsklinikum Halle
Recruiting
Halle, Germany
Contact: Toralf Bernig, Dr.
Universitätsklinikum des Saarlandes
Recruiting
Homburg, Germany
Contact: Norbert Graf, Prof.
Gesundheit Nordhessen - Klinikum Kassel
Recruiting
Kassel, Germany
Contact: Michaela Nathrath, Prof.
Universitätsklinikum Leipzig
Recruiting
Leipzig, Germany
Contact: Holger Christiansen, Prof.
UMM Universitätsmedizin Mannheim
Recruiting
Mannheim, Germany
Contact: Matthias Dürken, PD Dr.
Johannes Wesling Klinikum Minden
Recruiting
Minden, Germany
Contact: Bernhard Erdlenbruch, Prof.
Universitätsklinikum Münster
Recruiting
Münster, Germany
Contact: Ronald Sträter, PD Dr.
Klinikum Oldenburg gGmbH
Recruiting
Oldenburg, Germany
Contact: Hermann Müller, Prof.
Universitätsklinikum Regensburg
Recruiting
Regensburg, Germany
Contact: Marcus Jakob, Dr.
ASKLEPIOS Klinik St. Augustin
Recruiting
Sankt Augustin, Germany
Contact: Harald Reinhard, PD Dr.
Klinikum Stuttgart - Olgahospital
Recruiting
Stuttgart, Germany
Contact: Stefan Bielack, Prof.
Universitätsklinikum Tübingen
Recruiting
Tübingen, Germany
Contact: Martin Ebinger, PD Dr. 收起 <<
Brazil
... 展开 >> Hospital do Jurua
Recruiting
Cruzeiro do Sul, Brazil
Contact: Suiane Negreiros, MD omsvalle@hotmail.com
Principal Investigator: Suiane Negreiros, MD 收起 <<
Intermittent Preventive Treatm... 展开 >>ent In Pregnancy (IPTp) 收起 <<
Phase 3
Terminated(See termination rea... 展开 >>son in detailed description.) 收起 <<
-
Benin
... 展开 >> Centre de Santé d'AHOUANSORI-AGUE
Cotonou, Benin
Hôpital Bethesda
Cotonou, Benin
Kenya
Siaya District Hospital
Siaya, Kenya
Malawi
Zomba Central Hospital
Zomba, Malawi
Tanzania
Teule Hospital
Muheza, Tanga, Tanzania
Bugando Medical Centre
Mwanza, Tanzania, 1903
Nyamagana District Hospital, c/o National Institute for Medical Research, Mwanza Centre
Mwanza, Tanzania
Nyamagana District Hospital
Mwanza, Tanzania
Uganda
Mulago Hospital Complex
Kampala, Uganda 收起 <<
Ghana
... 展开 >> Pfizer Investigational Site
Navrongo, Ghana
Mali
Pfizer Investigational Site
Bamako, Mali
Uganda
Pfizer Investigational Site
Jinja, Uganda
Pfizer Investigational Site
Kampala, Uganda
Zambia
Pfizer Investigational Site
Ndola, Zambia 收起 <<
Philippines
... 展开 >> Kalinga Health Center
Tabuk, Kalinga Province, Philippines
Davao Health Center
Davao City, Mindinao, Philippines
Palawan Health Center
Puerto Princesa, Palawan, Philippines 收起 <<
Korea, Republic of
... 展开 >>
Asan Medical Center
Recruiting
Seoul, Korea, Republic of, 05505
Contact: JooYong Lee, Professor +82-2-3010-3976 ophthalmo@amc.seoul.kr 收起 <<
United States, Texas
... 展开 >>
Houston Methodist Hospital Cancer Center
Recruiting
Houston, Texas, United States, 77030
Contact: Cancer Center Research 713-441-0629 ccresearch@houstonmethodist.org
Principal Investigator: Jenny Chang, MD
Sub-Investigator: Angel A. Rodriguez, MD
Sub-Investigator: Daniel Lehane, MD
Sub-Investigator: Monisha Singh, MD
Sub-Investigator: Tejal Patel, MD
Sub-Investigator: Jorge Darcourt, MD
Houston Methodist Hospital Willowbrook
Recruiting
Houston, Texas, United States, 77070
Contact: Houston Methodist Cancer Center 713-441-0629 ccresearch@houstonmethodist.org
Principal Investigator: Anna Belcheva, MD
Houston Methodist Hospital Sugar Land
Recruiting
Sugar Land, Texas, United States, 77479
Contact: Houston Methodist Cancer Center 713-441-0629 ccresearch@houstonmethodist.org
Principal Investigator: Jorge Darcourt, MD 收起 <<
India
... 展开 >> Pfizer Investigational Site
Dispur Guwahati, Assam, India, 781006
Pfizer Investigational Site
Bambolim, Gao, India, 403002
Pfizer Investigational Site
Nagpur, Maharashtra, India, 440 018
Pfizer Investigational Site
Parel Mumbai, Maharashtra, India, 400012
Pfizer Investigational Site
Rourkela, Orissa, India, 769005
Pfizer Investigational Site
Vellore, Tamil Nadu, India, 632 004
Pfizer Investigational Site
Indore, India, 452001 收起 <<
Suspended(At the end of the ye... 展开 >>ar 2002, Cameroon switched from chloroquine to amodiaquine as first-line therapy for of uncomplicated malaria.) 收起 <<
-
Cameroon
... 展开 >> Institute of Medical Research and study of Medicinal Plants, Medical Research Center
Yaounde, Cameroon 收起 <<
Brazil
... 展开 >> Hospital Geral Maternidade de Cruzeiro do Sul
Cruzeiro do Sul, Acre, Brazil
Hospital Municipal Teonila Alves
Anajas, Para, Brazil
Centro de Pesquisa em Patologias Tropicais
Porto Velho, Rondonia, Brazil 收起 <<
Burkina Faso
... 展开 >> Pfizer Investigational Site
Nouna, Burkina Faso
Pfizer Investigational Site
Ouagadougou 01, Burkina Faso
Pfizer Investigational Site
Ouagadougou, Burkina Faso
Côte D'Ivoire
Pfizer Investigational Site
Abidjan 13, Côte D'Ivoire
Ghana
Pfizer Investigational Site
Navrongo, Ghana
Kenya
Pfizer Investigational Site
Kisumu, Kenya, 40100
Mali
Pfizer Investigational Site
Bamako, West Africa, Mali
Pfizer Investigational Site
Sikasso, West Africa, Mali 收起 <<
Colombia
... 展开 >> Pfizer Investigational Site
San Andres de Tumaco, Narino, Colombia
India
Pfizer Investigational Site
Bambolim, Goa, India, 403002 收起 <<
United States, Maryland
... 展开 >>
Clinical Research Unit, Uniformed Services University of Health Sciences
Not yet recruiting
Bethesda, Maryland, United States, 20814
Contact: Thomas Oliver, MD 301-295-0016 thomas.g.oliver.mil@mail.mil
WRAIR
Recruiting
Silver Spring, Maryland, United States, 20910
Contact: Jeffrey R Livezey, MD 301-319-3217 jeffrey.r.livezey.mil@mail.mil 收起 <<
United States, Alabama
... 展开 >>
Alabama Therapeutics CRS (5801)
Birmingham, Alabama, United States, 35294
United States, California
Ucsd, Avrc Crs (701)
San Diego, California, United States, 92103
United States, Colorado
University of Colorado Hospital CRS (6101)
Aurora, Colorado, United States, 80045
United States, District of Columbia
Georgetown University CRS (GU CRS) (1008)
Washington, District of Columbia, United States, 20007
United States, Maryland
Johns Hopkins Adult AIDS CRS (201)
Baltimore, Maryland, United States, 21205
United States, Massachusetts
Massachusetts General Hospital ACTG CRS (101)
Boston, Massachusetts, United States, 02114
United States, Missouri
Washington University CRS (2101)
St. Louis, Missouri, United States, 63110
United States, New York
Cornell CRS (7804)
New York, New York, United States, 10011
United States, North Carolina
Unc Aids Crs (3201)
Chapel Hill, North Carolina, United States, 27514
United States, Ohio
Univ. of Cincinnati CRS (2401)
Cincinnati, Ohio, United States, 45267
Case CRS (2501)
Cleveland, Ohio, United States, 44106
MetroHealth CRS (2503)
Cleveland, Ohio, United States, 44109
United States, Pennsylvania
Hosp. of the Univ. of Pennsylvania CRS (6201)
Philadelphia, Pennsylvania, United States, 19104
Pittsburgh CRS (1001)
Pittsburgh, Pennsylvania, United States, 15213
United States, Tennessee
Vanderbilt Therapeutics CRS (3652)
Nashville, Tennessee, United States, 37204 收起 <<
Malaysia
... 展开 >> Kota Marudu District Hospital
Recruiting
Kota Marudu, Sabah, Malaysia
Contact: Matthew Grigg, MBBS +60149569476 mat_grigg@hotmail.com
Principal Investigator: Timothy William, MBBS
Sub-Investigator: Tsin W Yeo, MBBS
Sub-Investigator: Nicholas M Anstey, MBBS
Sub-Investigator: Bridget E Barber, MBBS
Sub-Investigator: Jayaram Menon, MBBS
Sub-Investigator: Ric N Price, MBBS
Sub-Investigator: Matthew J Grigg, MBBS
Kudat District Hospital
Recruiting
Kudat, Sabah, Malaysia
Contact: Matthew Grigg, MBBS +60149569476 mat_grigg@hotmail.com
Sub-Investigator: Tsin W Yeo, MBBS
Sub-Investigator: Nicholas M Anstey, MBBS
Sub-Investigator: Bridget E Barber, MBBS
Sub-Investigator: Prabakaran Dhanaraj, MBBS
Sub-Investigator: Jayaram Menon, MBBS
Sub-Investigator: Ric N Price, MBBS
Principal Investigator: Timothy William, MBBS
Sub-Investigator: Matthew J Grigg, MBBS
Pitas District Hospital
Recruiting
Pitas, Sabah, Malaysia
Contact: Matthew Grigg, MBBS +60149569476 mat_grigg@hotmail.com
Principal Investigator: Timothy William, MBBS
Sub-Investigator: Tsin W Yeo, MBBS
Sub-Investigator: Nicholas M Anstey, MBBS
Sub-Investigator: Bridget E Barber, MBBS
Sub-Investigator: Jayaram Menon, MBBS
Sub-Investigator: Ric N Price, MBBS
Sub-Investigator: Matthew J Grigg, MBBS 收起 <<
Burkina Faso
... 展开 >> Pfizer Investigational Site
Ouagadougou, West Africa, Burkina Faso, 01
Pfizer Investigational Site
Nouna, Burkina Faso
Ghana
Pfizer Investigational Site
Navrongo, West Africa, Ghana
Kenya
Pfizer Investigational Site
Kisumu, Kenya, 40100
Mali
Pfizer Investigational Site
Bamako, West Africa, Mali
Pfizer Investigational Site
Bamako, Mali
Senegal
Pfizer Investigational Site
Senegal, West Africa, Senegal
Zambia
Pfizer Investigational Site
Ndola, Zambia 收起 <<
Pakistan
... 展开 >> Adezai Basic Health Unit
Adezai, Nwfp, Pakistan
Baghicha Basic Health Unit
Baghicha, Nwfp, Pakistan
Kagan Basic Health Unit
Kagan, Nwfp, Pakistan 收起 <<
Breast Cancer
... 展开 >> Invasive Breast Cancer 收起 <<
Phase 2
Unknown
March 2018
Canada, Ontario
... 展开 >>
The Ottawa Hospital Woman's Breast Health Centre
Recruiting
Ottawa, Ontario, Canada
Contact: Angel Arnaout, Dr. 613-798-5555
Principal Investigator: Angel Arnaout, Dr. 收起 <<
Asymptomatic Parasitemia In Pr... 展开 >>egnancy 收起 <<
Phase 3
Terminated(See termination rea... 展开 >>son in detailed description.) 收起 <<
-
Benin
... 展开 >> Centre de Sante d'AHOUANSORI -AGUE
Cotonou, Benin
Hôpital Bethesda
Cotonou, Benin
Kenya
Siaya District Hospital
Siaya, Kenya
Malawi
Zomba Central Hospital
Zomba, Malawi
Tanzania
Teule Hospital
Muheza, Tanga, Tanzania
National Institute for Medical Research (Mwanza Centre)/ Nyamagana District Hospital
Mwanza, Tanzania, 1903
Uganda
Mulanda Health Centre IV
Kampala, Uganda 收起 <<
Malaysia
... 展开 >> Kota Marudu District Hospital
Kota Marudu, Sabah, Malaysia, 89108
Kudat District Hospital
Kudat, Sabah, Malaysia, 89057
Pitas District Hospital
Pitas, Sabah, Malaysia 收起 <<
Malaysia
... 展开 >> Kota Marudu District Hospital
Kota Marudu, Sabah, Malaysia
Kudat District Hospital
Kudat, Sabah, Malaysia, 89057
Pitas District Hospital
Pitas, Sabah, Malaysia 收起 <<
United States, Florida
... 展开 >>
University of South Florida
Recruiting
Tampa, Florida, United States, 33606
Contact: Nhi Tran, MS 813-259-0628 nntran@health.usf.edu
Contact: Jacob Siddoway jsiddoway@health.usf.edu
Principal Investigator: Sami Noujaim, PhD
Sub-Investigator: Bengt Herweg, MD
Sub-Investigator: Dany Sayad, MD 收起 <<
United States, Ohio
... 展开 >>
University of Cincinnati Cancer Institute
Recruiting
Cincinnati, Ohio, United States, 45267-0502
Principal Investigator: Nagla Karim, MD, PhD
Sub-Investigator: Johm Morris, MD
Sub-Investigator: Sadia Benzaquin, MD
Sub-Investigator: Pankaj Desai, MS, PhD
Sub-Investigator: James Driscol, MD
Sub-Investigator: Ahmed Khaled, MD
Sub-Investigator: Jun Ying, PhD 收起 <<
United States, Virginia
... 展开 >>
Medical Oncology and Hematology Associates of Northern Virginia
Fairfax, Virginia, United States, 22031
Virginia Cancer Specialists, PC
Fairfax, Virginia, United States, 22031
Virginia Surgery Associates
Fairfax, Virginia, United States, 22033
Inova Fairfax Hospital
Falls Church, Virginia, United States, 22042 收起 <<
Netherlands
... 展开 >> NKI/AvL
Amsterdam, Netherlands
VU Medical Center
Amsterdam, Netherlands
Maastricht Radiation Oncology
Maastricht, Netherlands
Maastricht University Medical Center
Maastricht, Netherlands 收起 <<
Brazil
... 展开 >> Oswaldo Cruz Foundation
Rio de Janeiro, Brazil, 21040-360
Institute of Biomedical Sciences, University of Sao Paulo
São Paulo, Brazil, 05508-900 收起 <<
Netherlands
... 展开 >> VU University Medical Center
Not yet recruiting
Amsterdam, Noord-Holland, Netherlands, 1081 HZ
Contact: Myra E Van Linde, M.D. +31(20)4441412 m.vanlinde@vumc.nl
Academic Medical Center
Recruiting
Amsterdam, Noord-Holland, Netherlands, 1105AZ
Contact: Hanneke W Wilmink, M.D., Ph.D. +31(20)5662895 j.w.wilmink@amc.uva.nl
Contact: Remco J Molenaar, M.Sc. +31(20)5668587 r.j.molenaar@amc.nl
Principal Investigator: Hanneke W Wilmink, M.D., Ph.D.
Leiden University Medical Center
Not yet recruiting
Leiden, Zuid-Holland, Netherlands, 2333 ZA
Contact: Hans J Gelderblom, M.D., Ph.D. +31(71)5269111 A.J.Gelderblom@lumc.nl 收起 <<
搜索
